2018
July 2, 2018
Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology
May 8, 2018
Successful Delivery of DNAtrix’s Oncolytic Virus DNX-2401 to Pediatric Brain Tumors
April 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 American Association for Cancer Research Annual Meeting
2017
December 5, 2017
DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401
November 20, 2017
Mechanism of Action Studies for DNAtrix’s Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting
November 13, 2017
DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting
May 11, 2017
DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer
April 24, 2017
Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula
2016
November 17, 2016
DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology
November 8, 2016
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform
November 1, 2016
DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA
August 4, 2016
DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401
July 27, 2016
DNAtrix Receives European Medicines Agency PRIME Designation
February 9, 2016
DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors